Concession prices granted by the UK Department of Health and Social Care targeted some, but not all, of the fastest-rising generics prices in November. The average cost of some presentations more than trebled, according to the latest figures from WaveData.

A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.

Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.

Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.

Price movements seen among recently-launched generics in the UK do not always reflect changes in reimbursement prices, according to the latest figures from WaveData.